Published in Acta Oncol on January 01, 2006
Skin involvement and breast cancer: are T4b lesions of all sizes created equal? J Am Coll Surg (2014) 0.77
Magnetic resonance imaging evaluation of noninflammatory breast cancer with skin involvement after neoadjuvant chemotherapy. Ann Surg Oncol (2010) 0.75
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol (2006) 3.00
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol (2011) 2.72
The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat Med (2008) 2.70
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum Immunol (2006) 2.54
Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med (2007) 2.49
Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology (2003) 2.27
Intact fetal cells in maternal plasma: are they really there? Lancet (2003) 2.09
The first analysis and clinical evaluation of native breast tissue using differential phase-contrast mammography. Invest Radiol (2011) 2.08
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol (2012) 2.00
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst (2002) 1.90
Size separation of circulatory DNA in maternal plasma permits ready detection of fetal DNA polymorphisms. Clin Chem (2004) 1.79
Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology (2005) 1.73
Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol (2009) 1.67
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One (2012) 1.61
Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol (2002) 1.59
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol (2012) 1.54
The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol (2011) 1.50
Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol (2003) 1.49
In utero haematopoietic stem cell transplantation. Experiences in mice, sheep and humans. Swiss Med Wkly (2006) 1.49
Cesarean section due to fetal distress increases the number of stem cells in umbilical cord blood. Transfusion (2008) 1.45
Potential markers of preeclampsia--a review. Reprod Biol Endocrinol (2009) 1.44
In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology (2003) 1.40
Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centers. Oncology (2011) 1.40
Retroperitoneoscopic living donor nephrectomy: a retrospective comparison to the open approach. Transplantation (2004) 1.39
Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin Immunopathol (2007) 1.37
Implant-based breast reconstruction using a titanium-coated polypropylene mesh (TiLOOP Bra): a multicenter study of 231 cases. Plast Reconstr Surg (2013) 1.33
Metastatic patterns at autopsy in patients with ovarian carcinoma. Cancer (2007) 1.28
Optimized real-time quantitative PCR measurement of male fetal DNA in maternal plasma. Clin Chem (2005) 1.27
Novel real-time quantitative PCR test for trisomy 21. Clin Chem (2002) 1.26
Digital PCR: a powerful new tool for noninvasive prenatal diagnosis? Prenat Diagn (2008) 1.24
Interlaboratory comparison of fetal male DNA detection from common maternal plasma samples by real-time PCR. Clin Chem (2004) 1.23
Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer (2009) 1.20
Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol (2006) 1.18
SMAD7 is a prognostic marker in patients with colorectal cancer. Int J Cancer (2003) 1.18
Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res (2007) 1.17
Neutrophil NETs: a novel contributor to preeclampsia-associated placental hypoxia? Semin Immunopathol (2007) 1.15
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res (2007) 1.15
Intraspecific competition between co-infecting parasite strains enhances host survival in African trypanosomes. Ecology (2009) 1.15
Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res (2004) 1.15
Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. BMC Cancer (2009) 1.14
Detection of paternally inherited fetal point mutations for beta-thalassemia using size-fractionated cell-free DNA in maternal plasma. JAMA (2005) 1.10
Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer. Neoplasia (2009) 1.10
A study on mastectomy samples to evaluate breast imaging quality and potential clinical relevance of differential phase contrast mammography. Invest Radiol (2014) 1.10
Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol (2006) 1.09
[(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer (2009) 1.08
Sirenomelia, the mermaid syndrome--detection in the first trimester. Prenat Diagn (2003) 1.08
Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol (2006) 1.07
Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology (2005) 1.07
A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie (2008) 1.07
Tumor size and detection in breast cancer: Self-examination and clinical breast examination are at their limit. Cancer Detect Prev (2008) 1.06
Genetic investigations of CFTR mutations in congenital absence of vas deferens, uterus, and vagina as a cause of infertility. J Androl (2008) 1.05
High-throughput hacking of the methylation patterns in breast cancer by in vitro transcription and thymidine-specific cleavage mass array on MALDI-TOF silico-chip. Mol Cancer Res (2008) 1.05
Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet (2007) 1.05
Sexual dysfunction after premenopausal stage I and II breast cancer: do androgens play a role? J Sex Med (2008) 1.04
Board examination for anatomical pathology in Switzerland: two intense days to verify professional competence. Virchows Arch (2012) 1.03
Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis. Clin Chem (2007) 1.03
Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer. J Cancer Res Clin Oncol (2009) 1.03
Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol Rep (2005) 1.02
Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet (2010) 1.02
Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer. Mod Pathol (2010) 1.01
Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease. Anticancer Res (2008) 1.01
The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy (2002) 1.00
Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol (2008) 0.99
The multipotency of luteinizing granulosa cells collected from mature ovarian follicles. Stem Cells (2009) 0.98
Non-invasive prenatal detection of achondroplasia in size-fractionated cell-free DNA by MALDI-TOF MS assay. Prenat Diagn (2007) 0.98
PTEN as a molecular marker to distinguish metastatic from primary synchronous endometrioid carcinomas of the ovary and uterus. Diagn Mol Pathol (2003) 0.98
Detection of fetal DNA and RNA in placenta-derived syncytiotrophoblast microparticles generated in vitro. Clin Chem (2004) 0.98
The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res (2003) 0.98
DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Int J Cancer (2002) 0.97
Treatment of maternal blood samples with formaldehyde does not alter the proportion of circulatory fetal nucleic acids (DNA and mRNA) in maternal plasma. Clin Chem (2005) 0.97
Sentinel lymph node procedure leads to upstaging of patients with resectable colon cancer: results of the Swiss prospective, multicenter study sentinel lymph node procedure in colon cancer. Ann Surg Oncol (2012) 0.96
Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer (2006) 0.96
Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work? Breast Cancer Res Treat (2011) 0.96
Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther (2008) 0.96
Amplification of SKI is a prognostic marker in early colorectal cancer. Neoplasia (2004) 0.96
Molecular investigation of lymph nodes in colon cancer patients using one-step nucleic acid amplification (OSNA): a new road to better staging? Cancer (2012) 0.95
Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res (2011) 0.95
Micronutrients and women of reproductive potential: required dietary intake and consequences of dietary deficiency or excess. Part I--Folate, Vitamin B12, Vitamin B6. J Matern Fetal Neonatal Med (2010) 0.95
IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC Med (2010) 0.94
Occurrence of neutrophil extracellular DNA traps (NETs) in pre-eclampsia: a link with elevated levels of cell-free DNA? Ann N Y Acad Sci (2006) 0.94
Gastric necrosis complicating lately a Nissen fundoplication. Report of a case. Langenbecks Arch Surg (2007) 0.94
Indeterminate adnexal masses at ultrasound: effect of MRI imaging findings on diagnostic thinking and therapeutic decisions. Eur Radiol (2010) 0.93
Non-inflammatory skin involvement in breast cancer, histologically proven but without the clinical and histological T4 category features. J Surg Oncol (2007) 0.92
Nucleic acid based biosensors: the desires of the user. Bioelectrochemistry (2005) 0.92
Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res (2005) 0.92